Drug intelligence / Profile preview

LTX-001

Development stage: Phase 1
Lead developer: Leal Therapeutics
Modality: Small Molecules

Overview

LTX-001 is an investigational small molecule drug developed by Leal Therapeutics. It acts as a glutaminase 1 (GLS1) inhibitor, targeting glutamate presynaptic pathways. The drug is being explored for the treatment of central nervous system disorders, specifically schizophrenia, major depressive disorder (MDD), and amyotrophic lateral sclerosis (ALS). As of late 2024, LTX-001 remains in preclinical development for these indications. Its mechanism involves modulation of glutaminase activity to influence glutamate signaling, which is implicated in neuropsychiatric and neurodegenerative diseases[1][2][3].

Targets

GLS1 (Glutaminase 1)

Beyond the preview

Go deeper on LTX-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LTX-001.

Explore the full profile